XOMA Royalty Gelecekteki Büyüme

Future kriter kontrolleri 5/6

XOMA Royalty kazanç ve gelirinin sırasıyla yıllık 74.3% ve 32.6% oranında artması tahmin edilirken, EPS'nin yıllık 76.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

74.3%

Kazanç büyüme oranı

76.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.3%
Gelir büyüme oranı	32.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	14 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Aug 14

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Aug 11

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Aug 04

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

May 08

Xoma Gets The Spotlight

Sep 02

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Aug 20

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

May 13

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

May 11

XOMA EPS misses by $0.55, misses on revenue

May 06

XOMA gets milestone payment from Janssen Biotech

May 03

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Mar 17

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Mar 16

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Mar 09

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Feb 02

XOMA: A Royalty Aggregator To Watch

Jan 04

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Dec 29

XOMA prices $22M offering of series A cumulative perpetual preferred stock

Dec 11

Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Dec 01

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:XOMA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	46	2	N/A	N/A	3
12/31/2025	34	-8	N/A	N/A	3
12/31/2024	26	4	N/A	N/A	3
6/30/2024	15	-25	-8	-8	N/A
3/31/2024	6	-42	-13	-18	N/A
12/31/2023	5	-46	-18	-18	N/A
9/30/2023	4	-32	-18	-18	N/A
6/30/2023	4	-31	-20	-20	N/A
3/31/2023	3	-30	-14	-17	N/A
12/31/2022	6	-23	-13	-13	N/A
9/30/2022	40	10	42	22	N/A
6/30/2022	41	10	36	22	N/A
3/31/2022	41	12	36	23	N/A
12/31/2021	38	8	23	23	N/A
9/30/2021	30	1	-11	10	N/A
6/30/2021	29	6	-3	10	N/A
3/31/2021	29	6	-2	11	N/A
12/31/2020	29	9	10	10	N/A
9/30/2020	2	-13	-12	-12	N/A
6/30/2020	11	-9	-18	-5	N/A
3/31/2020	11	-10	-25	-6	N/A
12/31/2019	18	-2	-20	0	N/A
9/30/2019	20	-2	-18	1	N/A
6/30/2019	12	-8	-27	-5	N/A
3/31/2019	13	-6	-21	-6	N/A
12/31/2018	5	-13	-28	-13	N/A
9/30/2018	9	-11	-30	-15	N/A
6/30/2018	44	9	18	18	N/A
3/31/2018	53	18	N/A	13	N/A
12/31/2017	53	6	N/A	3	N/A
9/30/2017	48	-11	N/A	15	N/A
6/30/2017	12	-39	N/A	-28	N/A
3/31/2017	2	-61	N/A	-32	N/A
12/31/2016	6	-54	N/A	-34	N/A
9/30/2016	53	-11	N/A	-12	N/A
6/30/2016	55	1	N/A	-19	N/A
3/31/2016	57	-7	N/A	-23	N/A
12/31/2015	55	-21	N/A	-31	N/A
9/30/2015	12	-53	N/A	-77	N/A
6/30/2015	15	-67	N/A	-74	N/A
3/31/2015	18	-55	N/A	-74	N/A
12/31/2014	19	-38	N/A	-78	N/A
9/30/2014	27	-83	N/A	-68	N/A
6/30/2014	28	-99	N/A	-65	N/A
3/31/2014	29	-104	N/A	-60	N/A
12/31/2013	35	-124	N/A	-46	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: XOMA önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: XOMA önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: XOMA önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: XOMA şirketinin gelirinin (yıllık 32.6% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: XOMA şirketinin gelirinin (yıllık 32.6% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: XOMA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

XOMA Royalty Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 64%

Consensus revenue estimates fall by 58%

Consensus revenue estimates fall by 33%

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Recent updates

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Consensus revenue estimates increase by 64%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue

XOMA gets milestone payment from Janssen Biotech